NP: Normal persons; BCP: Breast cancer patients CONCLUSIONS This study investigates discriminating tongue features to distinguish between BCPs and normal people, and establishes differentiating index to facilitate the non-invasive detection of BC. The Mann–Whitney test showed that the amount of tongue...
(Fig.4c, d). This demonstrates the power of methylation clocks in tracing ancestral cell populations applied for the first time to ctDNA. It is also important to note that these high-resolution single-molecule data cost over 1000 less to generate than the respective whole-genome sequencing, ...
Compared to nomograms based on molecular profiling and imaging, STAR presents a more cost-effective, with potential savings of approximately $700-800 per breast cancer patient. Conclusion: Combining appropriate RT parameters, STAR nomogram could help in the detection of patien...
A novel breast cancer index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes. Clin Cancer Res. 2017... Y Zhang,BE Schroeder,PL Jerevall,... - 《Clinical Cancer Research》 被引量: 2发表: 2017年 Cost effectiveness of letrozole versus anastro...
KOHLER B A, SHERMAN R L, HOWLADER N, et al. Annual report to the nation on the status of cancer. 1975-…
The cost of breast cancer screening in the Medicare population. JAMA Internal Med. Published online January 7, 2013. doi: 10.1001/jamainternmed.2013.1397. eTable 1. Elixhauser conditions included in comorbidity index eTable 2. Screening and downstream breast procedures 1. Bach PB. Limits on ...
This paper reports the most cost-effective policy options to support and improve breast cancer control in Costa Rica and Mexico. Total costs and effects of breast cancer interventions were estimated using the health care perspective and WHO-CHOICE method
Conclusion Nab-PTX Q3 was likely to be cost-effective for metastatic breast cancerMBC in China compared with DTX Q3 when theunder the condition of 3 times Per Capita Gross National Product of China willingness-to-pay(WTP) thresholds were $178,980/QALY. 展开 ...
Research Date range: 1 September 2023 - 31 August 2024 Research collaboration: Breast Cancer Association Consortium (BCAC) is a research collaboration whose article contributions are accrued to its participating partner institutions.Partner Institutions Breast Cancer Association Con...
One key harm that researchers are concerned about, besides the possible extra cost, is the chance of a false-positive result. Supplemental imaging in women who aren’t at high risk for breast cancer may identify potential trouble spots, which can lead to follow-up testing such as breast biops...